Physician profile
Peter Marlin
NPI 1982694683
$2,486.63
in general payments reported to CMS, 2019-2025
19 companies · $1,044 in 2025
The $1,044 reported for 2025 was more than what 82% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $12.69 · 2023: $309 · 2024: $1,120 · 2025: $1,044.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,414 · Education: $59.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,413.95 |
| Education | $59.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $404.00 | 2023-2025 | |
| Alkermes, INC. | $341.89 | 2024-2025 | Aristada, Lybalvi, Aristada Initio |
| Otsuka America Pharmaceutical, INC. | $316.87 | 2023-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $285.39 | 2024-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Lundbeck LLC | $265.30 | 2023-2025 | Rexulti, Brintellix |
| E.R. Squibb & Sons, L.L.C. | $176.12 | 2025 | Cobenfy |
| Neurocrine Biosciences, INC. | $134.77 | 2023-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $121.76 | 2023-2025 | Caplyta |
| Tempus Ai, INC | $105.91 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $86.51 | 2023-2025 | Trintellix |
| Idorsia Pharmaceuticals US INC | $61.94 | 2022-2024 | Quviviq |
| Janssen Pharmaceuticals, INC | $44.76 | 2023-2024 | Spravato |
| Indivior INC. | $34.04 | 2024 | Sublocade |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.97 | 2025 | |
| Tris Pharma INC | $20.77 | 2025 | Dyanavel Xr |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $19.42 | 2025 | Auvelity |
| Collegium Pharmaceutical, INC. | $15.73 | 2025 | Jornay Pm |
| Ironshore Pharmaceuticals INC. | $14.49 | 2024 | |
| Supernus Pharmaceuticals, INC. | $13.99 | 2025 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Marlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.